Atypical Hemolytic Uremic Syndrome News and Research

RSS
Researchers identify a promising method to stop COVID-19 infection

Researchers identify a promising method to stop COVID-19 infection

New technique to detect common cause for diseases related to thrombotic microangiopathies

New technique to detect common cause for diseases related to thrombotic microangiopathies

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

TSRI scientists reveal how vision-loss treatment may leave the eyes, kidneys vulnerable to cellular damage

TSRI scientists reveal how vision-loss treatment may leave the eyes, kidneys vulnerable to cellular damage

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Alexion initiates new global Uncommon Strength campaign to raise awareness of rare diseases

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

New lab blood test may help identify HELLP syndrome in pregnant women

New lab blood test may help identify HELLP syndrome in pregnant women

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Machaon Diagnostics' aHUS Genetic Panel confirms atypical Hemolytic Uremic Syndrome in 48 hours

Machaon Diagnostics' aHUS Genetic Panel confirms atypical Hemolytic Uremic Syndrome in 48 hours

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients